BENITEC BIOPHARMA INC. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c676621f-79e1-4d49-aefd-7854c9007d04/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-41.8M | 2024-07-01 – 2025-06-30 | evidence 0001193125-25-211361 |
| FY 2024 | $-22.5M | 2023-07-01 – 2024-06-30 | evidence 0001193125-24-226968 |
| FY 2023 | $-19.1M | 2022-07-01 – 2023-06-30 | evidence 0001193125-23-239121 |
| FY 2022 | $-17.9M | 2021-07-01 – 2022-06-30 | evidence 0001193125-22-237075 |
| FY 2021 | $-13.6M | 2020-07-01 – 2021-06-30 | evidence 0001193125-21-276758 |
| FY 2020 | $-8.3M | 2019-07-01 – 2020-06-30 | evidence 0001193125-20-252381 |
| FY 2019 | $2.6M | 2018-07-01 – 2019-06-30 | evidence 0001193125-20-252381 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).